MEDICLINIC INTERNATIONAL LIMITED - Trading statement unaudited group results for the six months ended 30 September 2013

MEDICLINIC INTERNATIONAL LIMITED
(Incorporated in the Republic of South Africa)
(Registration number: 1983/010725/06)
(Share code: MDC)
(ISIN: ZAE000074142)
("Mediclinic" or 'the Company')


TRADING STATEMENT ' UNAUDITED GROUP RESULTS FOR THE SIX MONTHS
ENDED 30 SEPTEMBER 2013


Mediclinic is in the process of finalising its interim results for

the six months ended 30 September 2013, which are due to be

released on SENS on 6 November 2013 and published in the press on

7 November 2013 ('interim results announcement'). In terms of the

JSE Limited ('JSE') Listings Requirements, companies are required

to publish a trading statement as soon as they are satisfied that

a reasonable degree of certainty exists that the financial results

for the period to be reported upon next will differ by at least

20% from that of the previous corresponding reporting period.


Accordingly, shareholders are advised that the Company's basic

earnings per share ('EPS') and basic headline earnings per share

('HEPS') for the six months ended 30 September 2013 are expected

to be between 17% and 27% higher than that reported for the

previous corresponding reporting period ('the EPS and HEPS
range').


Shareholders are also advised that for the six months ended

30 September 2012, as well as for the year ended 31 March 2013,

the income statement and earnings per share have been restated due
to:

  - the adoption of the revised IAS 19 standard relating to
    employee benefits; and

  - an adjustment to the weighted average number of shares in

    issue subsequent to the 2012 rights offer in terms of IAS 33
    (paragraph 26).


This trading statement will also address normalised HEPS, which is

defined as reportable HEPS in terms of accounting standards,
excluding one-off items.


The one-off items included in calculating the EPS and HEPS range
are the following:

  - a past service cost credit     in one of the Group's pension
    funds in the current period; and

  - net unrealised gains on foreign exchange forward contracts in
    the previous period.


Excluding these one-off items, the normalised HEPS for the six

months ended 30 September 2013 are expected to be between 30% and

40% higher than that reported in the previous corresponding

reporting period and between 53% to 63% higher than the restated

numbers of the previous corresponding reporting period.


The financial information on which this trading statement is based

has not been reviewed and reported on by the Company's external
auditors.

Stellenbosch
28 October 2013


Mediclinic Offices, Strand Road, Stellenbosch 7600, South Africa
PO Box 456, Stellenbosch 7599, South Africa
Tel +27 21 809 6500
Fax +27 21 886 4037
Ethics line: 0800 005 316
Website: www.mediclinic.com

Sponsor

RAND MERCHANT BANK (A division of FirstRand Bank Limited)


Date: 28/10/2013 02:42:00 Supplied by www.sharenet.co.za                     
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.